Quick Answer
Actinium Pharmaceuticals, Inc. reported R&D Expense of $21.12 million for fiscal year 2025.
Actinium Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $21.12M | -29.7% |
| 2024 | $30.05M | -22.3% |
| 2023 | $38.67M | +67.1% |
| 2022 | $23.14M | +28.3% |
| 2021 | $18.03M | +12.1% |
| 2020 | $16.09M | -2.8% |
| 2019 | $16.55M | -3.2% |
| 2018 | $17.09M | -3.5% |
| 2017 | $17.72M | -0.6% |
| 2016 | $17.83M | +32.0% |
| 2015 | $13.50M | +10.1% |
| 2014 | $12.27M | +294.5% |
| 2013 | $3.11M | -9.6% |
| 2012 | $3.44M | +962.6% |
| 2011 | $323.8K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.25M | -56.5% | -12.9% |
| June 30, 2025 | $4.88M | -44.7% | -36.6% |
| March 31, 2025 | $7.70M | +16.1% | -21.2% |
| September 30, 2024 | $9.77M | -15.9% | +10.8% |
| June 30, 2024 | $8.82M | -20.4% | +33.0% |
| March 31, 2024 | $6.63M | -15.5% | -42.9% |
| September 30, 2023 | $11.62M | +71.6% | +4.9% |
| June 30, 2023 | $11.08M | +137.7% | +41.2% |
- Actinium Pharmaceuticals, Inc. showed a decrease of -29.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Actinium Pharmaceuticals, Inc.’s r&d expense has grown by 6424.0% (from $323.8 thousand to $21.12 million).
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: